お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
704952

消化器治療薬の世界市場 - 成長率、動向、予測:2019年~2024年

Gastrointestinal Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 113 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.27円
消化器治療薬の世界市場 - 成長率、動向、予測:2019年~2024年
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 113 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

消化器治療薬市場は、主に消化管疾患につながるライフスタイルの変化によって促進されています。2017年のNational Health Interview Surveyによると、米国において1530万人の成人が潰瘍と診断されました。

当レポートでは、世界における消化器治療薬市場の分析を薬剤タイプ・剤形・適応症および地域別に提供しており、競合情勢、主要企業のプロファイルなどとともにお届けします。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場促進要因
  • 市場抑制要因
  • ファイブフォース分析

第5章 市場区分

  • 薬剤タイプ別
    • 制酸薬
    • 便秘薬
    • 止瀉薬
    • 制吐薬
    • 抗潰瘍薬
    • その他
  • 剤形別
    • 経口薬
    • 非経口薬
    • その他
  • 適応症別
    • 潰瘍性大腸炎
    • 過敏性腸症候群
    • クローン病
    • セリアック病
    • 胃腸炎
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbott Laboratories
    • Allergan PLC
    • アステラス製薬
    • AstraZeneca
    • Bayer AG
    • GlaxoSmithKline PLC
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • Pfizer Inc.
    • AbbVie, Inc.
    • 武田薬品工業

第7章 市場機会と将来動向

目次
Product Code: 62814

The gastrointestinal therapeutics market is expected to register a healthy CAGR of nearly 6.5 % during the forecast period. The major factors that contribute to the growth of the gastrointestinal therapeutics market include the increasing prevalence of gastrointestinal diseases due to unhealthy dietary habits, additional numbers of clinical trials with accurate results, increasing healthcare expenditure, and growth in the geriatric population.

According to the National Health Interview Survey (2017), 15.3 million adults were diagnosed with ulcers in the United States. Therefore a wide range of new generation therapeutics is found targeting that include novel small molecules and cellular therapy are currently under investigation. Other driving factors include the rising surgical treatments and hospitalizations, due to GI diseases, and increasing R&D investments by biopharmaceutical companies in developing biologics and biosimilars.

However, risk factors, such as those related to the physiological, behavioral, psychosocial, and socio-environmental aspects, restrict the populations from reporting the diseases early, which reflects the low awareness and the economic burden. These risk factors and the increasing number of patent expirations restrict the growth of the gastrointestinal therapeutics market.

Key Market Trends

Ulcerative Colitis is Found to Witness Healthy CAGR Over the Forecast Period

Ulcerative colitis is found to witness rapid growth in the gastrointestinal therapeutics market. The growth of this segment can be attributed to the easy availability of drugs in the market to treat this condition. The segment is also anticipated to grow at a considerable rate owing to high clinical urgency to curb the growing prevalence of ulcerative colitis. This high prevalence is due to poor prognosis and consumption of unhealthy food, which may result in a high probability of disease recurrence. In addition, Takeda Pharmaceuticals, Jassen Pharmaceuticals, and Pfizer are among the major global companies that have established themselves with their products for the treatment of inflammatory ulcerative colitis.

Asia-Pacific is the Fastest Growing Region in the Gastrointestinal Therapeutics Market

In recent years, the Asian countries have been witnessing a similar growth trend to that of the western developed markets, particularly owing to the increasing economic growth, along with the privatization, competitive site experience, technological expertise, infrastructure, and the scale to manage large-scale clinical trials across India, China, Japan, South Korea, and other countries. The unmet medical need and potential market opportunity have accelerated the partnerships between major global companies and Asian pharmaceutical companies, for the development and exploration of commercial potential in the growth of the pharmaceutical business.

The North America market has also been accounted for the largest share and is expected to maintain its position during the forecast period. This substantial share can be attributed to unprecedented change in lifestyle, resulting in greater incidence of gastrointestinal diseases.

Competitive Landscape

The major players in the gastrointestinal therapeutics market include Abbott, Allergan, GlaxoSmithKline PLC, Pfizer, and Takeda Pharmaceutical Company Limited, among others. These key players have extensively employed competition sustainability strategies such as new product development and regional and distribution channel expansion to gain a higher share in the market. Moreover, increased focus on refining operation and supply chain management has facilitated key players to maintain a competitive edge.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of GI Diseases
    • 4.2.2 Rising Investments in R&D by Pharmaceutical Companies
  • 4.3 Market Restraints
    • 4.3.1 Rising Socio-economic Burden Associated with Gastrointestinal Disorders
    • 4.3.2 Increasing Number of Patent Expiries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Drug Type
    • 5.1.1 Antacids
    • 5.1.2 Laxatives
    • 5.1.3 Antidiarrheal agents
    • 5.1.4 Antiemetics
    • 5.1.5 Antiulcer agents
    • 5.1.6 Other Drug Types
  • 5.2 Dosage Form
    • 5.2.1 Oral
    • 5.2.2 Parenteral
    • 5.2.3 Other Dosage Forms
  • 5.3 Application
    • 5.3.1 Ulcerative Colitis
    • 5.3.2 Irritable Bowel Syndrome
    • 5.3.3 Crohn's Disease
    • 5.3.4 Celiac Disease
    • 5.3.5 Gastroenteritis
    • 5.3.6 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Abbvie (Allergan PLC)
    • 6.1.3 Astellas Pharma Inc.
    • 6.1.4 AstraZeneca
    • 6.1.5 Bayer AG
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Janssen Pharmaceuticals Inc. (Johnson & Johnson)
    • 6.1.8 Pfizer Inc.
    • 6.1.9 AbbVie Inc.
    • 6.1.10 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.